Sertraline is more effective than imipramine in the treatment of non-melancholic depression: Results from a multicentre, randomized study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 3, 2003, Pages 493-500

  Baca, Enrique ^a   González De Chávez, Manuel ^b   García Toro, Mauro ^c   Pérez Arnau, Francisco ^d   Porras Chavarino, Alberto ^e  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c Hospital Psiquiatrico (GESMA)   (Spain)

^d El Prat de Llobregat   (Spain)

^e PFIZER INC   (United States)

Author keywords

Clinical trial; Depressive disorder; Dysthymic disorder; Imipramine; Sertraline

Indexed keywords

IMIPRAMINE; SERTRALINE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTRITIS; HAMILTON SCALE; HUMAN; HYPERHIDROSIS; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MELANCHOLIA; MULTICENTER STUDY; OBSERVATION; OPEN STUDY; OUTPATIENT; PARALLEL DESIGN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; SCORING SYSTEM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREMOR; VERTIGO; VOMITING; XEROSTOMIA;

EID: 0037402532     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(03)00038-1     Document Type: Article

References (30)

1. Diagnostic and Statistical Manual of Mental Disorders. Revised. 3rd ed. 1987;American Psychiatric Press, Washington, DC.
2. Amsterdam J. Selective serotonin reuptake inhibitor efficacy in severe and melancholic depression. J. Psychopharmacol. 12:1998;S99-S111. (Suppl.).
3. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disord. 58:2000;19-36.
4. Brady K., Pearlstein T., Asnis G.M., Baker D., Rothbaum B., Sikes C.R., Farfel G.M. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA. 283:2000;1837-1844.
5. Brawman-Mintzer O., Rickels K., Rynn M., Knapp R., Weihs K., Shrivastava R.K., Tilker H., Patterson W., Sambunaris A., Rapaport M. A placebo-controlled, double-blind, flexible dosage study to evaluate the efficacy and tolerability of sertraline in the treatment of DSM-IV generalized anxiety disorder. Eur. Neuropsychopharmacol. 12(Suppl. 3):2002;S365.
6. Davidson J.R., Rothbaum B.O., van der Kolk B.A., Sikes C.R., Farfel G.M. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch. Gen. Psychiatry. 58:2001;485-492.
7. Deakin J.F.W. Does selectivity matter? Int. Clin. Psychopharmacol. 11(Suppl. 1):1996;13-17.
8. Frank E., Prien R.F., Jarrett R.B., Keller M.B., Kupfer D.J., Lavori P.W., Rush A.J., Weissman M.M. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch. Gen. Psychiatry. 48:1991;851-855.
9. Geddes J.R., Freemantle N., Mason J., Eccles M.P., Boynton J. SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst. Rev. 2:2002;. CD001851.
10. Greist J.H., Jefferson J.W., Kobak K.A., Chouinard G., DuBoff E., Halaris A., Kim S.W., Koran L., Liebowtiz M.R., Lydiard B. A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int. Clin. Psychopharmacol. 10:1995;57-65.
11. Guy W. Clinical global impressions. Guy W. ECDEU Assessment Manual for Psychopharmacology. 1976;217-222 NIMH, Rockville.
12. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 23:1960;56-62.
13. Hamilton M. Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 6:1967;278-296.
14. Kasper S., Fuger J., Moller H.J. Comparative efficacy of antidepressants. Drugs. 43(Suppl. 2):1992;11-22.
15. Kernick D.P. Which antidepressant? A commentary from general practice on evidence- based medicine and health economics. Br. J. Gen. Pract. 47:1997;95-98.
16. Kessler R.C., Nelson C., McGonagle K.A., Liu J., Swartz M., Blazer D.G. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br. J. Psychiatry. 168(Suppl. 30):1996;17-30.
17. Londborg P.D., Wolkow R., Smith W.T., DuBoff E., England D., Ferguson J., Rosenthal M., Weise C. Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br. J. Psychiatry. 173:1998;54-60.
18. Lydiard R.B., Perera P., Batzar E., Clary C.M. From the bench to the trench: a comparison of sertraline treatment of major depression in clinical and research patient samples. Prim. Care Companion. 1:1999;154-162.
19. Moller H.J. Pharmacotherapy of depressed patients. Increasing the therapeutic arsenal with a new generation of antidepressive drugs. Fortschr. Med. 115:1997;30-36.
20. Olfson M., Fireman B., Weissman M.M., Leon A.C., Sheehan D.V., Kathol R.G., Hoven C., Farber L. Mental disorders and disability among patients in a primary care group practice. Am. J. Psychiatry. 154:1997;1734-1740.
21. Pohl R.B., Wolkow R.M., Clary C.M. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am. J. Psychiatry. 155:1998;1189-1195.
22. Pollack M.H., Otto M.W., Worthington J.J., Manfro G.G., Wolkow R. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch. Gen. Psychiatry. 55:1998;1010-1016.
23. Reimherr F.W., Chouinard G., Cohn C.K., Cole J.O., Itil T.M., Lapierre Y.D., Masco H.L., Mendels J. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J. Clin. Psychiatry. 51(Suppl. B):1990;18-27.
24. Revicki D.A., Turner R., Brown R., Martindale J.J. Reliability and validity of a health-related quality of life battery for evaluating outpatient antidepressant treatment. Qual. Life Res. 1:1992;257-266.
25. Rush, A.J., Trivedi, M.H., Fava, M., Nierenberg, A., Rosenbaum, J.F., Thase, M., Howland, R., Kupfer, D.J., Wisniewski, S., Quitkin, F., Sackheim, H., McGrath, P., 2002. Sequenced treatment alternatives to relieve depression (Star*D). Web site accessed on November 5, 2002: http://www.edc.gsph.pitt.edu/stard/ .
26. Sartorius N., Ustun T.B., Lecrubier Y., Wittchen H.U. Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. Br. J. Psychiatry Suppl. 30:1996;38-43.
27. Temple R., Ellenberg S.S. Placebo-controlled trials and active-control trials in the evaluation of new treatments: part 1. Ethical and scientific issues. Ann. Intern. Med. 133:2000;455-463.
28. Thase M.E., Entsuah A.R., Rudolph R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry. 178:2001;234-241.
29. Van Ameringen M.A., Lane R.M., Walker J.R., Bowen R.C., Chokka P.R., Goldner E.M., Johnston D.G., Lavallee Y.J., Nandy S., Pecknold J.C., Hadrava V., Swinson R.P. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am. J. Psychiatry. 158:2001;275-281.
30. World Health Organization The ICD-10 Classification of Mental and Behavioural Disorders. Diagnostic Criteria for Research. 1992;World Health Organization, Geneva.